MYGN — Myriad Genetics, Inc.

Myriad Genetics (MYGN) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 Revenue: $210 million, exceeding the high end of the pre-announced range; a 4% growth excluding the impact from UnitedHealthcare's GeneSight decision.
• Testing Volume: 382,000 test results delivered in Q4.
• Adjusted Gross Margin: 70%, down 190 basis points year-over-year due to revenue headwinds from GeneSight.
• Adjusted EBITDA: $14.3 million; Adjusted EPS: $0.04.
• Full Year 2025 Revenue: $824.5 million, with over 1.5 million test reports generated.

2. Strategic Updates and Business Highlights

• Oncology Testing: Continued strong performance in MyRisk tests, with 14% growth in affected and 11% in unaffected markets. Prolaris test volume grew 12% year-over-year.
• Mental Health: GeneSight revenues grew 9% year-over-year, with a record 38,000 ordering clinicians.
• New Product Launches: Upcoming launches include the AI-enhanced Prolaris test and the Precise MRD test for breast cancer, with an Alpha launch starting next week.
• Commercial Strategy: Focus on enhancing customer workflow and expanding sales teams, particularly in oncology and prenatal health.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: $860 million to $880 million, with an adjusted gross margin of 68%-69% and adjusted EBITDA between $37 million and $49 million.
• Q1 2026 Revenue Expectation: $200 million to $203 million, reflecting 2%-4% growth year-over-year, with anticipated challenges in prenatal testing volume.

4. Bad News, Challenges, or Points of Concern

• GeneSight Revenue Impact: Affected by UnitedHealthcare's coverage policy change, leading to a decline in average revenue per test.
• Prenatal Testing Decline: Volume decreased due to prior order management disruptions, with expectations of continued challenges in Q1 2026.
• ASP Pressure: Anticipated modest headwinds in average selling prices across the portfolio, primarily due to payer mix changes and competition.
• MRD Launch Risks: Potential delays in MolDX approval could impact revenue contributions from the new MRD tests.

5. Notable Q&A Insights

• Growth Confidence: Management expressed confidence in returning to high single-digit growth rates by 2027, driven by new product launches and recovery in the prenatal business.
• MRD Launch Strategy: The Alpha launch will be selective to gather user feedback before broader rollout, with a focus on operational efficiency and clinical performance metrics.
• Sales Strategy: A focused sales approach is being implemented, with dedicated teams for prenatal and oncology products to enhance market penetration and customer engagement.
• Customer Recovery: Efforts are underway to win back customers affected by prior operational issues, with optimism about future growth in the prenatal segment as new products are introduced.

Overall, Myriad Genetics is navigating challenges while positioning itself for growth through strategic product launches and enhanced commercial capabilities.